An outbreak of a rare form of Ebola in the Democratic Republic of the Congo (DRC) is on track to become the largest in recorded history, according to researchers at Imperial College London. Since May, the Bundibugyo virus has infected more than 11,000 people and claimed over 5,000 lives, the university reported in a news article published on 20 November 2026.

Professor Neil Ferguson, director of the Jameel Institute for Disease and Emergency Analytics at Imperial, said his team's modelling suggests the outbreak is already comparable in scale to the devastating 2014-15 West Africa epidemic. Based on current trends, transmission could still be occurring a year from now, he warned.

A major challenge, according to Ferguson, is that responders are likely detecting only about half of all cases. "One of the major challenges at the moment is we think we're probably only detecting about half of cases which are occurring," he said. He explained that roughly two-thirds of deaths are happening in communities, with many of those affected not coming forward for healthcare.

The affected regions — Ituri and North Kivu provinces — are each the size of small European countries, Ferguson noted, with limited infrastructure, a challenging security environment, and low community trust in authorities. "These are huge areas with limited infrastructure, a very challenging security environment, they are very poor areas and because of their history, there's very low community trust in authorities, in government and even in health authorities," he said.

Dr Aula Abbara, an honorary clinical associate professor at Imperial and advisor to Médecins Sans Frontières, said the outbreak is occurring on top of existing humanitarian crises. "This is all occurring in a time of severe funding cuts…and it's estimated more than 14 million people in the DRC are already in need of humanitarian assistance, many of whom live in the affected areas," she said. Abbara, who was in North Kivu in June, said she was struck by the degree of severe malnutrition and multiple co-existing outbreaks of diseases like cholera, measles and malaria.

One of the key difficulties with the Bundibugyo virus is that its early symptoms — fever, fatigue, joint pains, diarrhoea, vomiting — are non-specific and easily mistaken for malaria, typhoid or other common infections. "As a healthcare worker, it's very difficult to differentiate between BVD and other infections often seen in these areas," Abbara explained.

Compounding the problem, all currently licensed Ebola vaccines and monoclonal antibody treatments target the Zaire strain, not the Bundibugyo strain now circulating. "BVD was last seen in Uganda in 2007, and in the DRC in 2012, and unfortunately what that means is all the recent licensed Ebola vaccines and monoclonal antibodies are targeting the Zaire strain rather than the Bundibugyo strain that we're dealing with at the moment," Abbara said.

Clinical trials are now underway testing the existing Ervebo vaccine as well as two candidate vaccines — one from the University of Oxford and an RNA vaccine from Moderna. Ferguson said those trials should produce results early next year, with potential rollout from late February or early March. Trials are also assessing treatments including the antiviral Remdesivir and an experimental pan-Ebolavirus antibody called MBP134, as well as the oral antiviral Obeldesivir for post-exposure prophylaxis.

However, Abbara noted that children and pregnant women are often excluded from clinical trials, despite being among those at highest risk of poor outcomes. She also highlighted that sufficient doses of therapeutics may not be available to meet the needs of the current outbreak.

Healthcare workers face additional risks beyond infection, including heat exhaustion from wearing full personal protective equipment in tropical conditions. "Wearing full PPE limits the time that a healthcare worker can be in a facility down to about 45 minutes, perhaps 60 minutes," Abbara said. "These are very tropical areas where the outbreak's occurring and that can lead to heat exhaustion, dehydration, and manual dexterity becomes very difficult."

The indirect impact on the health system is also severe, with routine care for conditions like malaria and maternity services disrupted. "Fear is keeping people away from healthcare," Abbara said, adding that indirect deaths are likely substantial.

Both experts stressed that controlling the outbreak will require more than medical interventions. "Clearly, both vaccines and effective treatments would aid the response, but neither is a panacea," Ferguson said. Abbara added: "What we need is not only careful surveillance, medical care and diagnostics — all essential in an outbreak, but we must also work to build trust with the communities affected, reduce stigma and work very closely with the local responders to support healthcare access and trust in the services offered."

The first confirmed case of a UK national infected with the disease was also reported this month, with the patient returning to the UK for treatment at the Royal Free Hospital.